Yield10 Bioscience Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Yield10 Bioscience, Inc. (YTEN) Reports Q2 Loss of $0.24
August 9, 2018 4:06 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q2 EPS of ($0.24).
A key highlight of the second quarter is the completion of planting for our 2018 field tests of C3003, said Oliver P. Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. The results of these field tests will allow us to set the direction and priorities for the next steps in the evaluation and development of C3003 as a potentially valuable new... More



